Le Lézard
Classified in: Health
Subjects: NPT, PDT, FDA

Brain & Behavior Research Foundation Comments on FDA Approval of New Depression Treatment

NEW YORK, March 6, 2019 /PRNewswire/ -- The Brain & Behavior Research Foundation (BBRF) applauds the FDA for its approval of Esketamine nasal spray as a new medication for treatment of resistant depression. 

Committed to alleviating the suffering caused by mental illness by awarding grants that will lead to advances and breakthroughs in scientific research. (PRNewsFoto/Brain & Behavior Research ...)

Dr. Jeffrey Borenstein, a Manhattan psychiatrist and President & CEO of the Brain & Behavior Research Foundation, says, "The approval of Esketamine as a new medication for treatment resistant depression is welcome news for people and their families who are impacted by depression."  

"We are pleased that the Brain & Behavior Research Foundation funding of both early research and ongoing studies on rapid acting antidepressants has helped lead to this development of a new medication for treatment resistant depression," Dr. Borenstein adds.

Dr. Borenstein is available for further commentary on the research and implications of the approval of Esketamine. 

Since 1996, BBRF has awarded 90 grants totaling more than $6.5 million to fund research on rapid acting antidepressants conducted by scientists in the United States and abroad. One of these scientists is BBRF Young Investigator Carla M. Canuso, M.D., of Johnson & Johnson/Janssen R&D, whose paper, "Esketamine Reduced Suicidal Thoughts Within Hours of Treatment" published in the American Journal of Psychiatry in July 2018, was cited as one of the top 12 advances in psychiatric research from a BBRF-funded scientist in 2018. Among other scientists in the field who have received BBRF funding is Dr. Carlos A. Zarate, of the National Institutes of Mental Health, who was one of the early pioneers in the study of ketamine for the treatment of depression.

The Brain & Behavior Research Foundation
The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia. Since 1987, the Foundation has awarded more than $394 million to fund more than 4,700 leading scientists around the world, which has led to over $3.9 billion in additional funding. 100% of every dollar donated for research is invested in our research grants. The Foundation's operating expenses are covered by separate foundation grants.

For more information: The Brain & Behavior Research Foundation


SOURCE Brain & Behavior Research Foundation

These press releases may also interest you

at 14:40
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. ("Enzo" or the "Company"), today announced that Egan-Jones Proxy...

at 14:38
Chairman and CEO, Jeffrey M. Stamps, R.Ph., of Baltimore-based  Remedi SeniorCare, announces the opening of the company's newest PAXIT® pharmacy in Chicago, Illinois.  With the opening of its twelfth location, Remedi SeniorCare is licensed in 32...

at 14:33
As we have emphasized, the FAA and other global regulators will determine when the 737 MAX returns to service. However, in order to help our customers and suppliers plan their operations, we periodically provide them with our best estimate of when...

at 14:25
VerdePharmHealth and Base One Health today announced a national group purchasing agreement for procurement of cannabis products across the multi-specialty network. Both organizations aim to simplify the supply chain, lower costs, and provide broad...

at 14:15
The global cardiovascular devices market is expected to reach US$ 71.1 Bn in 2027 from US$ 40.8 Bn in 2018. The cardiovascular devices market is estimated to grow with a CAGR of 6.5% from 2019-2027. Read the full report:...

at 14:10
Atlantic Health System's Morristown Medical Center, nationally recognized for heart care, today opened the second of two new 36-bed units for patients with heart disease, completing a two-story expansion of the Gagnon Cardiovascular Institute....

News published on 6 march 2019 at 06:00 and distributed by: